The impact of the SIRPα mismatch on cGVHD observed in the current lymphoid cohort is similar to that seen in the AML/MDS cohort, However, in that study, the relapse protection effect was borderline statistical significant (P = 0.05), whereas a significant association was observed between the presence of SIRPα variant mismatch and reduced relapse (HR 0.5, P = .003) in the present study, which contributed to the significantly improved PFS (HR 0.5, P = .001). The gene discussed is SIRPA; the disease is myelodysplastic syndrome.